Available therapies for reducing OA pain include pharmacologic agents (e.g., acetaminophen, nonsteroidal antiinflammatory drugs [NSAIDs] , opioids, antidepressants such as duloxetine, topical ointments, and intraarticular injections), nonpharmacologic interventions (e.g., education, exercise, and lifestyle modifications), surgical approaches (arthroplasty), and psychological counseling (7, (10) (11) (12) . Existing pharmacologic treatments are associated with various side effects, including gastrointestinal, cardiovascular (13, 14) , neurologic, and narcotic (15, 16) . In addition, currently available pharmacologic treatments do not always provide sufficient pain relief, often do not improve functional status, and are contraindicated in some patients (17) (18) (19) . In many patients, the limited efficacy of these drugs and the higher occurrence of adverse events (AEs) limit their tolerability and reduce compliance (20) (21) (22) (23) . Poor tolerability in some patients even results in refusal to continue pharmacologic therapy despite pain at levels sufficient to require joint replacement (21) . Given the limitations of current therapies, there is an unmet need for alternative therapies that provide better efficacy, tolerability, and functionality in the long-term management of the signs and symptoms of OA.
Regulatory authorities have recently recommended the demonstration of maintained efficacy of new pharmacologic agents beyond the 12 weeks previously required (24, 25) . Long-term (.6 months) efficacy studies of existing pharmacologic agents (analgesics in general) are rare, and very few long-term placebo-controlled studies have demonstrated sustained analgesic efficacy in OA (26, 27) . Fulranumab, a human anti-nerve growth factor (anti-NGF) monoclonal antibody, was previously shown to have significant efficacy for improving pain and physical functioning and, was generally well tolerated in patients with moderate-to-severe chronic OA in a 12-week doubleblind efficacy phase study (28) . In the present study, we focused on the double-blind extension phase of the previously described primary study (28) . We describe herein the long-term safety and efficacy of fulranumab as adjunctive therapy to standard therapy for pain in patients with moderate-to-severe knee or hip pain caused by OA.
PATIENTS AND METHODS
Patients. The patient population in this study consisted of men and women ages 40-80 years with OA of the hip or knee who were receiving stable analgesic regimens of NSAIDs and/or immediate-release or long-acting opioids and were entering the double-blind phase of the initial trial (28) . For the current study, patients were required to have a mean OA pain intensity score of $5 (using an 11-point Numerical Rating Scale [NRS]), as averaged over the last 3 days of pain scores assessed before randomization. Other key inclusion and exclusion criteria are described in the previous report (28) .
The protocol and informed consent documents were reviewed and approved by an independent ethics committee or institutional review board at each study site. The study was conducted in accordance with the ethical principles of the Declaration of Helsinki and in accordance with the Good Clinical Practice guidelines of the International Conference on Harmonisation, as well as applicable regulatory requirements, and in compliance with the study protocol. All participants provided written informed consent to participate in the study.
Study design. This phase II, randomized, double-blind, placebo-controlled extension study was conducted at 85 sites in Canada, Korea, Poland, and the US from September 2009 to August 2011. The planned study included a 3-week screening phase, a 12-week double-blind efficacy phase, a 92-week doubleblind extension phase, and a 26-week posttreatment follow-up phase (total of 104 weeks of treatment). All treatments were stopped on December 23, 2010, when the US Food and Drug Administration (FDA) placed ongoing fulranumab studies on clinical hold because of the concern that the entire class of anti-NGF antibodies may be associated with potential treatmentemergent AEs (TEAEs) leading to joint destruction. At the time of the clinical hold, the longest fulranumab exposure in the study was 73 weeks.
During the 12-week double-blind efficacy phase, patients were randomized (1:1:1:1:1:1) to 1 of the following treatments: placebo or 1 of 5 fulranumab regimens (1 mg every 4 weeks, 3 mg every 8 weeks, 3 mg every 4 weeks, 6 mg every 8 weeks, and 10 mg every 8 weeks), as subcutaneous injections into the thigh or abdomen (28) . Patients continued on their randomized dose throughout the double-blind extension phase. During the 12-week double-blind efficacy phase, patients were required to maintain their concurrent pain medications without changes; however, they were allowed to change their concurrent pain medications as clinically needed during the double-blind extension phase. Dosage reductions of the study drug were allowed in patients who experienced new or worsening neurologic-related TEAEs. However, if neurologic symptoms persisted for 3 months, the patients were withdrawn from the study drug.
Efficacy assessments. Efficacy end points included changes over time from baseline in scores on the pain and physical function subscales of the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC; version 3.1) (29, 30) and the patient's global assessment (PGA) (31, 32) . Scores for individual items of WOMAC 3.1 were recorded using an NRS of 0-10 (with higher scores corresponding to greater pain/difficulty/stiffness). The PGA is a single-item assessment of each patient's perception of his or her OA status (11-point NRS, from 0 5 very good to 10 5 very bad). During the double-blind extension phase, the average PGA scores were recorded every 4 weeks, and the WOMAC pain and physical function subscale scores were recorded every 8 weeks.
Safety assessments. Safety assessments included evaluations of TEAEs, clinical laboratory test results, vital signs, physical examination findings, 12-lead electrocardiogram (EKG), and injection sites. Neurologic safety was assessed at every visit using an abbreviated neurologic examination, the Total Neuropathy Score-nurse (TNSn) (33) , and the Mini-Mental State Examination (34) . The TNSn was administered at all study visits as a screening tool. It consisted of targeted questioning of patients in 764 SANGA ET AL order to identify and quantify treatment-emergent impairment of sensory and motor function, autonomic symptoms, and pin and vibration sensibilities, and to facilitate neurologic evaluation, longitudinal monitoring, and trigger further neurologic consultations if needed. Changes from baseline in any TNSn subscore of .2 or total TNSn score .3 (scale of 0-4) were reviewed by the site investigator; all changes assessed to be clinically significant by the site investigator were referred to a neurologist for further assessment. Antidrug antibodies were also measured up to 6 months after the last dose of study drug. Due to concerns about joint safety during the study, all joint replacement surgery information was collected both retrospectively and prospectively from the time of the clinical hold until the end of the posttreatment follow-up phase. An independent data monitoring committee was appointed before the start of the study to review all unblinded safety data. After the 2010 clinical hold for the joint safety issue, a separate Independent Adjudication Committee (IAC) blinded with regard to treatment group was established by the sponsor to develop definitions of rapid progression of OA (RPOA) and osteonecrosis (ON) (Supplementary Table 1 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley. com/doi/10.1002/art.39943/abstract), consistent with the literature and the adjudicators' experience, as well as to review suspicious cases to render diagnoses based on radiologic information and to attribute causality based on clinical data. The IAC consisted of 5 external clinical experts from rheumatology, orthopedic surgery, and radiology, who had extensive clinical experience with patients with RPOA and ON.
The IAC reviewed clinical information (including radiographic images, pathology reports, and surgical notes, where available) for all patients who had joint replacements as well as for patients who had a sustained increase in pain that was not explained by another diagnosis, but did not undergo joint replacement and had radiographs taken because of the change in symptoms. Based on the assessment of joint radiographs, magnetic resonance images (MRIs) when available, and other clinical data (including pathology reports when available), the IAC adjudicated each case as one of the following: ON RPOA, RPOA with a component of, or advancing to, ON (RPOA plus ON), normal progression of OA (NPOA), or insufficient information. The IAC assessed case attributions based on blinded structural and clinical evidence and applied the following attributes: definitely related, probably related, possibly related, not related, or insufficient information. Each adjudicator was asked to grade each case on her or his own, and the final grading by each member was done following group discussions. It was required that at least 3 of the 5 IAC members agree on the assessment of the case for a given category to be designated as the collective IAC final assessment. Statistical analysis. All efficacy and safety analyses were performed on the intent-to-treat analysis set, which included all patients who had received at least 1 dose of fulranumab or placebo. During the double-blind extension phase, descriptive statistics over time and corresponding data were produced for all efficacy parameters. No prespecified statistical modeling was applied for efficacy assessments after week 16. As an exploratory analysis, a mixed model for repeated measures was fit based on measurements at weeks 5, 9, 13, 17, 25, 33, 41, and 49 using an unstructured covariance matrix. All safety evaluations were summarized descriptively. The combined safety results were presented for all phases of the study (double-blind efficacy plus double-blind extension plus posttreatment follow-up).
RESULTS

Patient disposition and baseline characteristics.
A total of 468 patients were randomized into the study. Of the 423 patients who completed the 12-week double-blind efficacy phase, 401 (95%) elected to enter the double-blind extension phase (Figure 1 ). All of them entered the posttreatment follow-up phase. Another 4 patients entered the posttreatment follow-up phase directly from the doubleblind efficacy phase. Thus, a total of 405 patients entered the 26-week posttreatment follow-up phase. The top 3 reasons for withdrawal from the double-blind extension phase were sponsor discontinuation of the study due to the FDA clinical hold (53%), patient's choice (13%), and AEs (11%). Two patients (one with paresthesia of the fingers of the right hand and the other with a tingling sensation in both arms) had neurologic symptoms (mild and possibly related to fulranumab treatment) that persisted for 3 months, but both of them recovered upon cessation of fulranumab treatment. Most patients (86%) completed the posttreatment follow-up phase. The demographic and baseline disease characteristics of the patients who entered the double-blind phase have been published elsewhere (28) . Table 1 shows the baseline characteristics of the patients who entered the double-blind extension phase.
Extent of treatment exposure. Although the study was planned for a 2-year treatment period (double-blind efficacy plus double-blind extension), due to the clinical hold, the median duration of drug exposure in the fulranumab groups ranged from 365 days to 393 days (Supplementary Table 2 ). Most patients (.98%) in all treatment groups did not require dosage adjustments during the study. Efficacy analysis. Due to the clinical hold, the efficacy end points could be summarized only up to week 49; there was sparse efficacy data available between weeks 49 and 73. Long-term improvements were observed in WOMAC pain and physical function subscales and PGA scores for the 1 mg every 4 weeks, 3 mg every 4 weeks, and 10 mg every 8 weeks fulranumab groups compared with placebo ( Figure 2 ). Numerical separations from placebo for scores on the WOMAC pain and physical function subscales and PGA were noted for the 1 mg every 4 weeks, 3 mg every 4 weeks, and 10 mg every 8 weeks fulranumab groups at weeks 33 and 41 ( Figure 2) . Based on the exploratory mixed model for repeated measures, the statistical significance at the 2-sided level of 0.1 was achieved by the 3 mg every 4 weeks and 10 mg every 8 weeks groups at weeks 33 and 41.
Safety analysis. Overall, 421 of the 466 patients in the intent-to-treat group (90%) experienced at least 1 TEAE during the study (all phases). The incidence of TEAEs was similar in the placebo group (88% [n 5 69]) and the overall fulranumab groups (91% [n 5 352]) ( Table 2 ). The most frequently reported TEAEs ($10% of patients) among all fulranumab-treated patients were arthralgia (21%), OA (18%) (e.g., exacerbation of OA pain), paresthesia (13%), and upper respiratory tract infection (13%), whereas among the placebo-treated patients, these were arthralgia (15%), OA (14%), and sinusitis (12%).
Overall, 28% of patients in the fulranumab groups had neurologic-related TEAEs, compared with 14% patients in the placebo group. The most common ($5% of patients) neurologic-related TEAEs in the fulranumab groups were paresthesia (13%), carpal tunnel syndrome (CTS) (8%), and hypoesthesia (7%) ( Table 2) . Only 3% of patients in the fulranumab groups discontinued the treatment due to neurologic-related TEAEs in the combined double-blind phase (paresthesia, CTS, dystonia, numbness of feet, decreased Achilles tendon reflex, lumbar radiculopathy, and muscle weakness). Two patients had serious neurologic-related TEAEs during the double-blind extension phase, which led to treatment discontinuation (CTS in 1 patient receiving fulranumab 3 mg every 4 weeks and syncope in 1 patient receiving fulranumab 10 mg every 8 weeks; both serious TEAEs were considered severe). The syncope case resolved on the same day and was considered to be unrelated to the study drug; however, treatment was discontinued due to the sponsor's decision to discontinue treatment on day 421. During the posttreatment follow-up phase, 7 fulranumab-treated patients (4 receiving 6 mg every 8 weeks and 3 receiving 10 mg every 8 weeks) and no placebo-treated patients experienced neurologic-related TEAEs. These neurologic-related TEAEs included a burning sensation ( Approximately one-third of the neurologicrelated TEAEs (n 5 40 [8%]) led to neurologic consultations (for placebo, 6%; for fulranumab, 3% taking 1 mg every 4 weeks, 9% taking 3 mg every 8 weeks, 11% taking 3 mg every 4 weeks, 10% taking 6 mg every 8 weeks, and 10% taking 10 mg every 8 weeks). Of these, 15 patients with neurologic TEAEs that lasted more than 15 days were confirmed to have neuropathy, which was diagnosed as either CTS (n 5 4; 1 taking placebo and 3 taking fulranumab), radiculopathy (n 5 2; both taking fulranumab), peripheral sensorimotor neuropathy (n 5 6; all taking fulranumab), or mixed neuropathy (n 5 3; 1 taking placebo and 2 taking fulranumab). All of these were documented to have recovered after cessation of therapy, except for 3 patients with peripheral neuropathies. Of these, 2 patients withdrew consent (one on day 140 and the other on day 176) while the TEAE was still present, but continued follow-up during the posttreatment follow-up phase until study completion. One patient continued the study drug despite the TEAE but was later withdrawn due to noncompliance with the protocol. The most frequent (.10 patients) neurologic AEs in the fulranumab-treated groups that did not resolve until the end of the study was CTS (n 5 11 [3.1%])
A total of 109 patients (23%) reported serious TEAEs: 13 taking placebo (17%) and 96 taking fulranumab (25%) ( Table 2 ). The most frequently occurring serious TEAEs ($5%) in fulranumab groups were knee arthroplasty (n 5 38 [10%]) and hip arthroplasty (n 5 26 [7%]). Of these, 25% were joint replacements for reasons that were not secondary to RPOA; these were advanced and long-term candidates for joint replacements.
Additional cases of joint replacement were reported after the end of the follow-up phase. A total of 71 patients reported having at least 1 joint replacement (total of 81 joint replacements) ( Table 3) . Among the 81 joint replacement surgeries, 46 involved the knee joint, 33 involved the hip joints, and 2 were in shoulder joint. Twenty-five of the joint replacements were in nonindex joints (10 hip, 13 knee, and 2 shoulder joints); the rest involved the index joints. Figure 3 describes the time to joint replacement surgery in placebo-and fulranumabtreated groups. The incidence rate for all joint * The cutoff date was July 10, 2011 for joint replacement. IRs 5 incidence rates (per 1,000 personyears); RPOA 5 rapid progression of osteoarthritis.
LONG-TERM SAFETY AND EFFICACY OF FULRANUMAB
replacements was 139 per 1,000 person-years in the fulranumab group and 98 per 1,000 person-years in the placebo group. All joint-related AEs (71 patients with joint replacements and 5 who had not undergone joint replacement surgery) were reviewed by the IAC. In the majority of patients with joint replacement, the procedure was determined by the IAC to be related to normal progression of OA (n 5 56 [79%]) followed by RPOA (n 5 15 [21%]) ( Table 3) . None of the cases assessed by the IAC were either ON or RPOA with features of ON. All cases adjudicated as RPOA occurred in patients receiving fulranumab and concurrent NSAIDs who had a history of OA in the affected joint. The mean 6 SD age of the patients with joint replacements was 61 6 9.01 years. A total of 58% were women, and 56% had a BMI of $30. The median number of injections received before surgery was 11 (range 1-17). Small changes from baseline were noted in the total and subscale scores on the TNSn.
An equal proportion of patients in the fulranumab and placebo groups (4% and 5%, respectively) had at least 1 neurologic consultation during the double-blind efficacy phase, while a higher percentage of patients receiving fulranumab at a dosage of 3 mg every 4 weeks (16%) had at least 1 neurologic consultation more than the other fulranumab groups and the placebo group (6-10%) in the double-blind extension phase (29 patients had objective findings). More patients in the fulranumab 6 mg every 8 weeks (3%) and 10 mg every 8 weeks (4%) groups with at least 1 neurologic examination had a change in total and subscale scores on the TNSn as compared with the other fulranumab groups and placebo (0-1%) during the double-blind efficacy phase, while more patients receiving fulranumab at a dosage of 3 mg every 4 weeks (12%) had a change in total and subscale scores on the TNSn as compared with the other fulranumab groups and placebo (3-7%) during the double-blind extension phase. There was no change in the TNSn suggestive of sympathetic dysfunction seen in this study.
No TEAEs that were indicative of hepatic or acute renal failure occurred during the study. Most injection-site reactions of redness, tenderness, swelling, or induration were also mild or moderate. No clinically meaningful changes were observed in laboratory test results, vital signs, or EKG findings. There were no deaths during the study.
DISCUSSION
The anti-NGF class is a potential option for patients who have had an ineffective response to available pharmaceutical analgesics. This class has demonstrated superior efficacy in the management of pain and improvement of physical functioning as compared with placebo, NSAIDs, and opioids, as well as superior tolerability as compared with opioids (26, 35) . We report herein the findings of our study of the long-term safety and analgesic efficacy of fulranumab when used as an adjunct to nonopioid or opioid OA analgesics. Approximately 90% of patients had as many as 12 months of exposure to fulranumab.
Fulranumab (at 3 mg every 4 weeks and 10 mg every 8 weeks) provided continued effective relief of pain associated with knee and hip OA as early as week 4, which was maintained up to week 53. The results of pain reduction were further corroborated by improvements in physical function noted in scores on the WOMAC physical function subscale and PGA following fulranumab treatment. Numerical separation of scores on the WOMAC pain and physical function subscales and PGA observed in the fulranumab 3 mg every 4 weeks and 10 mg every 8 weeks groups versus placebo throughout the study suggests sustained efficacy of longterm treatment with fulranumab (28) . The sawtooth pattern seen in the PGA scores for the lower dosage groups (those administered every 8 weeks) also suggests that dosing every 8 weeks does not result in sustained efficacy and that dosing every 4 weeks is preferred. Sustained efficacy in comparison to placebo has not previously been described for the existing pharmacologic therapies for OA.
The overall safety profile of fulranumab demonstrated that the proportion of patients reporting TEAEs among the fulranumab-treated groups (86-95%) was similar to that in the placebo group (88%). The types of TEAEs seen during this long-term extension study were not different from those observed during a 4-dose monotherapy study in a similar OA population (28) .
A number of clinical events were specifically monitored a priori as "events of interest" during the study, which included bradycardia, hypotension, neurologic signs or symptoms, renal failure, and hepatic failure. A study-mandated discontinuation was in effect for neurologic-related TEAEs (paresthesia, CTS, and hypoesthesia) if 3 monthly doses were missed. Of the remaining TEAEs, no other events of interest during this study were serious or led to discontinuation. Furthermore, although most patients with neurologicrelated TEAEs were documented to recover after stopping the study drug, future studies will exclude patients with active or recent CTS. There were no dose-related trends with regard to vital signs (blood pressure, pulse rate measures, EKGs), AEs, or individual items on the autonomic questionnaire element of the TNSn that would suggest that there was any effect of fulranumab on the sympathetic nervous system.
A joint-related safety signal, RPOA, resulting in rapid joint destruction leading to joint replacement surgery was identified as a specific safety concern by the FDA in clinical studies of anti-NGF drugs in development (36) . The available literature suggests that RPOA is a part of the natural spectrum of OA progression (37) . Patients with RPOA have OA that progresses at a much faster rate than routine OA does, with significant joint space narrowing and/or osteolysis occurring in , 1 year (38,39). The incidence rate of RPOA in the general population has not been well-described; however, an incidence rate of 15.2-18.2% has been reported in patients awaiting joint replacement surgery (40, 41) . Most of the available data on RPOA are based on hip OA; high incidence rates of RPOA in the knee have not been reported and have not been seen in large cohorts of knee OA patients. Although not identified as RPOA, rapid destruction of hip joints has been described with the use of potent NSAIDs such as indomethacin (42) .
All cases of RPOA in the current study, irrespective of whether these were in the target joint, appeared to be associated with combination therapy with fulranumab and NSAIDs in patients with preexisting OA, which is consistent with previous findings (43) . Published studies have also demonstrated an increased risk of RPOA for the combination of tanezumab and a long-term NSAID as compared with tanezumab monotherapy (44, 45) . Consistent with this, all cases of RPOA observed in the present study occurred in patients receiving combined therapy of fulranumab and NSAID use and in patients with a history of OA in the affected joint. However, due to the small number of RPOA cases per treatment group, a drug or dosage effect for RPOA could not be evaluated. Future studies are warranted to demonstrate whether limiting the use of concomitant long-term NSAIDs and using only lower doses of fulranumab may reduce the risk of RPOA.
Limitations of this study were that the study design did not support a statistical analysis of the dose or dosing frequency response and lacked an active comparator. Placebo-treated patients tended to stop therapy sooner than fulranumab-treated patients. Most of the joint safety information (radiographs, pathology reports, etc.) were collected retrospectively. In addition, since the study was shortened due to the clinical hold, not all patients were able to complete all of the planned treatments that would otherwise have provided clearer insight into the long-term tolerability and efficacy of fulranumab.
In this long-term, placebo-controlled study, fulranumab was generally well-tolerated in patients with chronic OA knee or hip pain, with the exception of RPOA emerging as a safety signal. Long-term (up to 1 year) efficacy of fulranumab therapy versus placebo was observed for 3 dosages: 1 mg every 4 weeks, 3 mg every 4 weeks, and 10 mg every 8 weeks. Dosing every 4 weeks is preferred, since it showed a better long-term efficacy profile than did dosing every 8 weeks. Despite the monthly dosing regimen and long half-life of fulranumab, patients experienced pain relief within a short period of time. Additional long-term studies comparing fulranumab therapy with current standard-ofcare treatment are warranted to demonstrate sustained efficacy and to assess the safety/tolerability of lower doses of fulranumab without concomitant use of longterm NSAIDs.
